Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

Healthcare Biotechnology
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Replicel Life Sciences Inc
Bullboard Posts
User Avatar Image
(21)
•••
Comment by RPINVESTOR1on Jan 08, 2020 11:48am
75 Views
Post# 30530714

RE:RE:RE:RE:RE:Gratitude & Promise

RE:RE:RE:RE:RE:Gratitude & PromiseIngiboy:-

If the results from Phase 2 Trials were bad, Shiseido should have no problem making the information known to Replicel. There would be no point in spending money on lawyers to litigate something of no value.

I have not seen anything official about Replicel taking legal action against Shiseido. I think it is either bluster from Lee B. or some deliberately misleading comments...like his pre-Christmas Tweet (implying details coming by December 25th!).

I think Shiseido wants world-wide rights to RCH01. There could be a bidding war for Replicel if the Phase 2 results are made public. I think they would like to take Replicel off the market before other large companies are fully aware of the situation. I don't see this happening until late February when the 2.7 million warrants expire (exercise price $2.00). 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities